1. Home
  2. MPU vs MNOV Comparison

MPU vs MNOV Comparison

Compare MPU & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MPU

Mega Matrix Corp.

HOLD

Current Price

$0.88

Market Cap

57.6M

ML Signal

HOLD

Logo Medicinova Inc

MNOV

Medicinova Inc

HOLD

Current Price

$1.43

Market Cap

72.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MPU
MNOV
Founded
1989
2000
Country
Singapore
United States
Employees
N/A
N/A
Industry
Transportation Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
57.6M
72.7M
IPO Year
2023
2004

Fundamental Metrics

Financial Performance
Metric
MPU
MNOV
Price
$0.88
$1.43
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$7.00
AVG Volume (30 Days)
363.6K
59.2K
Earning Date
01-01-0001
06-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,360,807.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
194.15
52 Week Low
$0.49
$1.13
52 Week High
$4.44
$1.96

Technical Indicators

Market Signals
Indicator
MPU
MNOV
Relative Strength Index (RSI) 54.70 43.77
Support Level $0.78 $1.40
Resistance Level $1.05 $1.62
Average True Range (ATR) 0.06 0.10
MACD 0.01 -0.01
Stochastic Oscillator 46.03 35.53

Price Performance

Historical Comparison
MPU
MNOV

About MPU Mega Matrix Corp.

Mega Matrix Inc is a holding company. It operates through its two subsidiaries Mega Metaverse Corp (Mega) and JetFleet Management Corp (JMC). The Company has two business segments which are comprised of : ETH staking business and The leasing of regional aircraft to foreign and domestic regional airlines. The majority of the company's revenue is earned through Leasing business segment. The company operates in USA and Canada, Asia-Pacific, Europe, Middle East and Africa, and Latin America.

About MNOV Medicinova Inc

MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.

Share on Social Networks: